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Renal disease and hypertension in non–insulin-dependent diabetes ease caused by non–insulin-dependent diabetes mellitus
mellitus. Recent epidemiologic data demonstrate a dramatic increase (NIDDM) is mounting [3, 4]. NIDDM accounts for
in the incidence of end-stage renal disease (ESRD) in patients with
nearly 90% of all cases of diabetes [5]. Nevertheless,non-insulin-dependent diabetes mellitus (NIDDM), thus dispelling the
mistaken belief that renal prognosis is benign in NIDDM. Currently, NIDDM-related renal disease has been relatively ig-
the leading cause of ESRD in the United States, Japan, and in most nored. The epidemiology, natural history, genetics, patho-
industrialized Europe is NIDDM, accounting for nearly 90% of all
genesis, and spectrum of renal lesions differ in patientscases of diabetes. In addition to profound economic costs, patients
with NIDDM and diabetic nephropathy have a dramatically increased with NIDDM versus IDDM. Progress has been made in
morbidity and premature mortality. NIDDM–related nephropathy var- preventing the renal complications of IDDM, yet the
ies widely among racial and ethnic groups, genders and lifestyles; and
utility of many of these measures in NIDDM has notgender may interact with race to affect the disease progression. While
the course of insulin-dependent diabetes mellitus (IDDM) progresses been determined.
through well-defined stages, the natural history of NIDDM is less well
characterized. NIDDM patients with coronary heart disease have a
higher urinary albumin excretion rate at the time of diagnosis and DEMOGRAPHIC ASPECTS OF NIDDM
follow-up. This greater risk may also be associated with hypertension
AND NEPHROPATHYand hyperlipidemia, and genes involved in blood pressure are obvious
candidate genes for diabetic nephropathy. Hyperglycemia appears to There has been an increase in the incidence of ESRD
be an important factor in the development of proteinuria in NIDDM,
in the past two decades [6] and a concomitant increasebut its role and the influence of diet are not yet clear. Tobacco smoking
can also be deleterious to the diabetic patient, and is also associated in diabetic ESRD patients. Between 1982 and 1992, pa-
with disease progression. Maintaining euglycemia, stopping smoking tients with diabetes as the cause of their ESRD rose
and controlling blood pressure may prevent or slow the progression of
from 27% to 36% in the United States and from 11%NIDDM-related nephropathy and reduce extrarenal injury. Treatment
recommendations include early screening for hyperlipidemia, appro- to 17% in Europe [7].
priate exercise and a healthy diet. Cornerstones of management should Data from the 1995 United States Renal Data System
also include: (1) educating the medical community and more widely
showed that nearly 40% of patients receiving renal re-disseminating data supporting the value of early treatment of microal-
buminuria; (2) developing a comprehensive, multidisciplinary team placement therapy (RRT) in 1992 had diabetes. In addi-
approach that involves physicians, nurses, diabetes educators and be- tion, 36.3% of the incident ESRD cases in 1992 were
havioral therapists; and (3) intensifying research in this field.
diabetic [1]. A high incidence of diabetic ESRD also
was evident in Canada (24%) [8], Australia (14%) [9],
Europe (17%) [10], and Japan (28%) [2] in the same year.
Diabetic nephropathy is the leading cause of end-stage Diabetic nephropathy is due predominantly to
renal disease (ESRD) in the United States, Japan, and NIDDM. The prevalence of NIDDM-related ESRD is
most of industrialized Europe [1–3]. Although attention probably underestimated. Incorrect reporting of NIDDM
has focused on renal disease and insulin-dependent dia- patients as IDDM when they require insulin therapy
betes mellitus (IDDM), a silent epidemic of renal dis- complicates classifying diabetes. Indeed, 35% to 45% of
NIDDM patients receive insulin [11]. Regional studies
suggest that NIDDM contributes significantly to diabeticKey words: ACE gene polymorphism, albuminuria, calcium channel
ESRD. In data from the Michigan Kidney Registry [12],blockers, diabetic nephropathy, hyperglycemia, hyperlipidemia, hyper-
tension, microalbuminuria, urinary albumin excretion. most black patients with diabetic ESRD had NIDDM
(77%), whereas white patients more often had IDDMReceived for publication September 15, 1997
as a cause of diabetic ESRD (58%). In Pima Indians,and in revised form April 8, 1998
Updated September 16, 1998 95% of diabetic ESRD is due to NIDDM [13]. Similarly,
61% of diabetic ESRD in Australia is due to NIDDM 1999 by the International Society of Nephrology
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[14], with a larger percentage in the aboriginal popula- are relatively low. However, the prevalence of NIDDM
nephropathy is 3.6 times greater in overseas French terri-tion [85%]. In Europe, NIDDM accounts for 43% of
diabetic ESRD. However, in the lower Neckar region of tories [14]. Even within metropolitan France, the inci-
dence of ESRD in NIDDM patients is lower in areasGermany, 90% of diabetic ESRD was NIDDM related
[4]. In Italy (national) and Lombardy (regional), NIDDM bordering Italy and Spain (countries with a low incidence
of NIDDM-related ESRD) compared with regions bor-accounted for 67% and 50% of diabetic ESRD, respec-
tively [15, 16]. dering Belgium and Germany (countries with a higher
incidence of ESRD from NIDDM) [27, 31, 32]. For in-Several explanations may account for the growth of
NIDDM-related nephropathy. According to a National stance, in Strasbourg, next to the German border, 40%
of all patients starting RRT in 1995 had NIDDM (Hanne-Health Interview Survey, there was an increase in diabe-
tes in the United States in 1993 [5]. The prevalence for all douche, personal communication). These data suggest
that environmental factors may influence the develop-ages was 3.1%, compared with 0.93% in 1958. NIDDM
accounted for almost 95% of this new diabetic popula- ment of ESRD in NIDDM.
tion. Similarly, in former communist Germany, the prev-
alence of diabetes increased from 1% in 1965 to 4% in
NATURAL HISTORY
1988 [17]. Western societies are also aging. Given the
IDDM-related nephropathy progresses through well-increased incidence of NIDDM with age [18], older pa-
defined stages [33], with ESRD arising 15 to 30 yearstients with ESRD are more likely to have NIDDM. Fi-
after the onset of diabetes. The natural history of ne-nally, NIDDM patient survival has improved. In regions
phropathy in NIDDM is less well characterized. The dateof Germany formerly under communist rule, where anti-
of onset of NIDDM is often unknown, and low-gradehypertensive treatment and treatment for coronary heart
albuminuria in NIDDM may be less specific as an indica-disease was not available in the early 1970s, 45% of
tor of disease progression. Age and hypertension canNIDDM patients died less than four years after the diag-
also affect renal function, and cardiovascular mortalitynosis of NIDDM [19]. In Heidelberg [20], the five-year
may not allow for the development of nephropathy insurvival for NIDDM patients after the onset of protein-
NIDDM.uria increased from 35% to 75% between 1966 and 1985,
The Pima Indians have provided useful informationallowing a greater percentage of these patients to experi-
about NIDDM. This Native American tribe has the high-ence progression to ESRD.
est prevalence of diabetes in the world (<70% of adultsNIDDM-associated nephropathy varies widely among
develop diabetes) [34]. They also have high rates of obe-racial and ethnic groups. NIDDM is more prevalent
sity and insulin resistance but rarely develop ketoacido-among African Americans, Hispanic Americans, and
sis. In contrast to most NIDDM patients, the onset ofNative Americans. African American males have twice
diabetes in Pima Indians usually occurs in the third orthe incidence of diabetes, and African American women
fourth decade of life [35], allowing for diabetic complica-have four times the incidence of diabetes compared with
tions to manifest themselves without the confoundingEuropean Americans [21–24]. Pugh et al found a sixfold
effects of age and age-related mortality.higher incidence of diabetic-related ESRD in Mexican
Americans compared with non–Hispanic whites and
Stage I: Hemodynamics of recent-onset NIDDMfound a fourfold increase in blacks [23]. Cowie et al also
Renal vasodilation and hyperfiltration occur early inshowed that diabetic ESRD was more common in blacks
IDDM [36]. This may not always be the case in NIDDM.[12]. Race-dependent risks of nephropathy may be re-
Scandinavian investigators, using single-shot 51Cr-EDTA,lated to glycemic control, hypertension, or other factors
noted normal glomerular filtration rates (GFR) at thesuch as differences in the quality and access to medical
time of diagnosis of diabetes [37]. Nowack et al alsocare [25, 26].
noted glomerular hyperfiltration in some (44%), but notGender may also affect the prevalence of NIDDM-
all, NIDDM patients [38]. Other investigators have dem-related nephropathy. According to the EDTA registry
onstrated hyperfiltration in NIDDM patients [39, 40].[27], 55% of NIDDM patients who began RRT in 1990
Pima Indians have an average GFR by iothalamate clear-were male. These data are similar to those from Minne-
ance that is 15% greater than nondiabetic control pa-sota [28] and Heidelberg [4]. However, gender may inter-
tients [35]. Most of the increase in GFR can be attributedact with race. Data from the 1988 United States Renal
to increased renal plasma flow (RPF) and a slight reduc-Data System reported that the relative risk of diabetic
tion in serum albumin resulting in decreased glomerularESRD for females compared with males was 1.20 in
oncotic pressure. However, for any given RPF, GFRblacks and 0.85 in whites [29].
was greater in diabetics than in controls, suggesting thatThere also may be a relationship between lifestyle
glomerular capillary hydrostatic pressure and/or the ul-and renal disease in NIDDM [30]. The incidence and
prevalence of NIDDM-associated nephropathy in France trafiltration coefficient were increased.
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Several factors may lead to hyperfiltration in NIDDM. not universally increased in NIDDM [51, 52]. Schmitz,
Christensen and Taagehoej found no significant differ-Glucose levels are higher in hyperfiltering patients [38],
and a link between hyperglycemia and hyperfiltration ences in glomerular volume comparing NIDDM patients
with normal UAE and matched nondiabetic controlshas been suggested by the direct correlation between
GFR and HbA1C [35]. Prostaglandins may play a role [53]. Interestingly, kidneys were significantly larger in
patients with elevated UAE, and the UAE increased toin hyperfiltration [41], as well as increased sodium (Na1)
glucose reabsorption in the proximal tubule. This re- a greater extent in patients with nephromegaly than in
those with normal-sized kidneys [54].duces Na1 delivery to the macula densa and alters tubu-
loglomerular feedback. Furthermore, in IDDM and Some NIDDM patients, however, do manifest glomer-
ular hypertrophy [26, 55]. Glomeruli in Pima IndiansNIDDM, there is a marked increase in GFR in response
to amino acid infusion. have been shown to be increased in size prior to the
onset of diabetes, yet their size does not increase furtherGFR decreases in response to metabolic control in
IDDM and NIDDM but usually not to levels found in with the development of diabetes [26]. Pagtalunan et al
found that glomerular volume was greater in Pima Indi-nondiabetic individuals [37, 42]. A mildly elevated uri-
nary albumin excretion (UAE) is frequently present at ans compared with live kidney donors, yet glomerular
volume was not significantly different in patients withthe time of diagnosis of diabetes. In 15% of newly diag-
nosed NIDDM patients, microalbuminuria remains evi- and without albuminuria [56]. Osterby et al also exam-
ined glomerular ultrastructure in biopsy samples fromdent despite glycemic control [43]. Moreover, GFR in
these patients is generally higher than in patients with proteinuric NIDDM patients and found that glomerular
hypertrophy correlated with mesangial volume [57].normal UAE [44].
Selective glomerular permeability Stage II: Early renal involvement
The earliest structural abnormality in diabetes is GBMThere is evidence for impaired glomerular charge and
size selectivity in NIDDM, and most of this information thickening. This occurs in nearly all patients [49], begin-
ning 1.5 to 2.5 years after the onset of IDDM. Thishas been provided by meticulous and regular studies in
the Pima Indian tribe. In the process, the authors have may be followed by an increase in fractional mesangial
volume (mesangial volume per glomerulus) in those pa-provided a paradigm for understanding changes in glo-
merular function in NIDDM. Myers et al found elevated tients whose renal disease progresses. These changes are
also present in NIDDM patients, although their timingfractional clearances of high molecular weight dextrans
in Pima Indians with NIDDM of recent onset (less than is less regular [58]. Recent work from Fioretto et al
demonstrated that a majority of NIDDM patients with3 years duration) [35]. Using certain assumptions, they
concluded that glomerular pores in NIDDM shifted to- microalbuminuria have normal-appearing glomeruli, or
nonspecific changes with interstitial and arteriolar le-ward a larger size. Impairment of barrier size selectivity
combined with a high GFR appeared to increase the sions [59]. Typical Kimmelstein-Wilson lesions of dia-
betic glomerulosclerosis are found in a much smallerfiltered protein load, resulting in a bimodal pore size
distribution. proportion of NIDDM patients early in the course of
nephropathy. In contrast, nonspecific vascular or intersti-The IgG to IgG4 clearance ratio has been used to
estimate charge selectivity in the glomerular capillary tial changes are prevalent in these patients. This apparent
difference from IDDM may be due to aging, ischemia,wall [45]. Endogenous proteins undergo variable rates
of tubular reabsorption; hence, this ratio reflects glomer- or both. There is no doubt, however, that in NIDDM
patients who come to autopsy, Kimmelstiel-Wilson le-ular and tubular protein handling [46]. Use of this ratio
suggests that impairment of the electrostatic barrier in sions are highly prevalent.
The extent of mesangial expansion appears to beglomeruli, as a consequence of decreased glycosamino-
glycans in the glomerular basement membrane (GBM) linked to the severity of renal dysfunction [49]. Mesangial
expansion and occlusion of glomerular capillaries lead[47], precedes the size-selective defect [45] and contrib-
utes to hyperfiltration early in diabetic renal disease. to a loss of available surface area for filtration and to a
decline in function [60, 61]. Glomerular hypertrophy mayInterestingly, Tamsma et al recently demonstrated that
GBM heparin sulfate was diminished in patients with initially compensate for this, providing a mechanism for
maintaining GFR [62]. Indeed, the rate of progressionglomerular disease, including NIDDM [48].
of diabetic renal disease may be limited by the capacity
Glomerular size and structure for glomerular expansion [63].
NIDDM patients with microalbuminuria tend to haveRenal and glomerular hypertrophy are evident early
in diabetes. In IDDM renal hypertrophy correlates with more advanced structural lesions than those with normal
UAE, although structural abnormalities may not corre-GFR [49, 50], but with insulin treatment there is a reduc-
tion in glomerular volume [50]. Glomerular volume is late with declining function [64, 65]. Glomerular volume
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fraction in diabetic patients with microalbuminuria is
greater, suggesting that microalbuminuria is an indicator
of diabetic renal disease, regardless of GFR [59].
Stage III: Initial stages of nephropathy
(microalbuminuria)
Normal UAE is defined as excretion of less than 30
mg/24 hr (less than 20 mg/min) or an albumin-to-creati-
nine ratio (A/C) less than 30 mg/g. Microalbuminuria is
defined as an albumin excretion rate between 20 and
200 mg/min or 30 to 300 mg/24 hr [66]. Patients with
microalbuminuria have a negative urine dipstick for pro-
tein and a 24-hour urine protein excretion within the
normal range. The greater sensitivity of measurements of
urinary albumin is due to the fact that albumin comprises
only a small proportion of protein in normal urine.
Microalbuminuria heralding diabetic nephropathy is Fig. 1. Ten-year survival by baseline urinary albumin concentrations
observed after 5 to 15 years of IDDM. In NIDDM, how- (UAC in mg/ml) after correction for age, duration of diabetes, and
serum creatinine concentration by a Cox regression analysis in 407ever, microalbuminuria may be present even before the
patients with NIDDM. Data are from Schmitz and Vaeth [80]. Line Aonset of diabetes. In the Mexico City Diabetes Study, is UAC # 15; line B is 15 , UAC # 40; line C is 40 , UAC # 200.
microalbuminuria was evident in nondiabetic individuals
with impaired glucose tolerance and in individuals with
positive family histories for diabetes [67]. The risk of
developing NIDDM was greater in patients with microal- gensen followed 278 normoalbuminuric and microal-
buminuric NIDDM patients for six years and noted thatbuminuria [67]. Elevated albumin excretion rate was also
present in 15% of Pima Indians with impaired glucose the change in albuminuria in normoalbuminuric patients
(mg albumin/ml 4.2 6 1.9 to 8.3 6 2.8) was less than intolerance [68]. Certainly, at the time of NIDDM diagno-
sis, microalbuminuria or frank albuminuria is present in microalbuminuric patients (36.4 6 1.9 to 96.9 6 4.0) [76].
Although in the past microalbuminuric patients werea large proportion of patients. In one study, 19% of newly
diagnosed NIDDM patients had microalbuminuria, and considered destined for nephropathy, better glycemic
control and the use of angiotensin (Ang) converting en-5% even had macroalbuminuria [69]. This was confirmed
by the UK Prospective Diabetes Study [70, 71], in which zyme (ACE) inhibition [77] have altered the risk of pro-
gression in IDDM [78]. The same may be true for17% of the patients had microalbuminuria. Keller et al
similarly found microalbuminuria in 14% and macroalbu- NIDDM, but microalbuminuria in NIDDM may be less
predictive of nephropathy because of comorbid condi-minuria in 2% of patients with newly diagnosed NIDDM
[43]. Although essential hypertension may be associated tions. Its association with cardiovascular mortality (vide
infra) reduces its predictive sensitivity (that is, deathwith microalbuminuria, blood pressure is apparently not a
major contributor to microalbuminuria in early NIDDM, before development of nephropathy).
as similar frequencies of microalbuminuria were found
Elevated UAE as a risk factor for deathin hypertensive and normotensive patients [43].
The point prevalence of elevated UAE in clinic-based Microalbuminuria in IDDM and NIDDM is associated
with an increased risk of cardiovascular death [74, 79,Danish NIDDM patients was 28% versus 14% for IDDM
[72]. Higher prevalence rates for microalbuminuria and 80]. Higher UAE rates were present in NIDDM patients
with coronary heart disease at diagnosis of diabetes [81]macroalbuminuria also have been reported in Pima Indi-
ans (26% and 21%, respectively) [68]. Microalbuminuria and in follow-up [72]. In another study, 503 NIDDM
patients were followed for 10 years [80]. Two percentin NIDDM may be more common than in IDDM. The
subtle variability in prevalence may depend on the pa- died from uremia, whereas 56% died from cardiovascu-
lar disease (CVD) or stroke [80]. Figure 1 shows survivaltient population, the duration of diabetes, and the pres-
ence of hypertension. curves for UAC after correcting for prognostic variables.
Even a minor increase in UAC, that is, 16 to 40 mg/ml,Microalbuminuria is predictive of progression to ne-
phropathy in IDDM [73]. It may not be as predictive in was associated with reduced probability of survival, and
the greater the level of albuminuria, the worse the prog-NIDDM. Mogensen noted that after 9.5 years, 22.4% of
patients with microalbuminuria developed proteinuria nosis. The hazard ratios in the elevated UAE groups
were 1.65 and 2.41 relative to those with UAE # 15 mg/(more than 400 mg/ml) compared with 5.4% of patients
with normoalbuminuria [74, 75]. Schmitz, Vaeth and Mo- ml. Interestingly, no further increase in mortality was
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Table 1. Mean values of HbA1C and mean blood pressure and may be due to a period of unrecognized hyperglycemia
incidence of microalbuminuria
prior to the diagnosis of NIDDM [93].
Incidence of Renal risk was assumed to be less in NIDDM [94]. The
Parameter microalbuminuria P value Joslin Clinic reported that the cumulative renal mortality
HbA1C , 9.5% 4/22 (18.2%) rate by the age 75 was 7.5% in NIDDM [95], and the, 0.05
. 9.5% 7/12 (58.3%)
proportion of NIDDM patients dying from renal diseaseMean blood pressure , 95 mmHg 4/21 (19.0%)
, 0.05
. 95 mmHg 7/13 (53.8%) was as low as 1.6% to 2.0% [96]. Furthermore, the rela-
tive risk of renal death was increased only twofold com-Adapted from Haneda et al, with permission [86].
pared with the general population [97]. In contrast, dia-
betic nephropathy with renal failure was the cause of
death in 42% of patients with IDDM who were below
detected in patients with UAE more than 200 mg/ml. age 20 at the onset of IDDM [98]. It is not surprising,
The association of microalbuminuria with hypertension therefore, that interest in the clinical manifestations and
and hyperlipidemia accounts for part of the cardiovascu- pathophysiology of diabetic nephropathy centered al-
lar risk in NIDDM. The “Steno” hypothesis postulated most exclusively on IDDM until now.
that albuminuria was a harbinger of endothelial dysfunc- In Pima Indians [99], the incidence of proteinuria was
tion and subsequent atherogenesis. A preliminary study 23% after 15 years of diabetes and 50% after 20 years,
lent support to this idea [82], as NIDDM patients with refuting the notion that nephropathy was less common
albuminuria had higher plasma levels of von Willebrand in NIDDM. The onset of heavy proteinuria correlated
factor than patients without albuminuria. This observa- with the duration and severity of diabetes, as in IDDM.
tion was consistent with the concept that microalbuminu- The cumulative incidence of proteinuria in two popula-
ria may serve as a surrogate marker of endothelial cell tions with IDDM and in two populations with NIDDM
dysfunction [83]. In general, microalbuminuria appears is compared in Figure 2. The incidence in NIDDM is at
to be a marker for atherosclerotic disease and death in least as high as in IDDM [100]. Hasslacher et al showed
NIDDM. When it precedes a diagnosis of NIDDM, it a similar risk for proteinuria at any given duration of
may be a marker of the prediabetic state, occurring with diabetes in IDDM and NIDDM patients [101]. The risk
hypertension, hyperlipidemia, hyperinsulinemia, and in- of proteinuria after 25 years of disease was 57% in
sulin resistance [67]. In populations with lower cardiac NIDDM and 46% in IDDM. The risk of renal failure,
risk, such as the Japanese or Pima Indians, microalbumin- that is, serum creatinine more than 1.4 mg/dl, after five
uria may not be as predictive of coronary death [84, 85]. years of persistent proteinuria was 63% and 59% in
Because microalbuminuria is a predictor of mortality NIDDM and IDDM, respectively.
as well as proteinuria in NIDDM, it is important to High-grade albuminuria correlated with several fac-
identify the factor(s) responsible for its development and tors. Males had a higher prevalence of albuminuria (20%
progression. Poor glycemic control and hypertension are males vs. 6% in females) [72], and the prevalence of
strongly associated with microalbuminuria (Table 1) hypertension increased with escalating degrees of albu-
[86]. Increased levels of atrial natriuretic peptide [87] minuria [102]. Albuminuria has been linked to the pres-
and renal endothelial dysfunction [88, 89] predate overt ence of proliferative retinopathy, coronary heart disease,
nephropathy [89]. Elevated plasma prorenin levels [90] and foot ulcers. In Pima Indians with NIDDM, the pres-
have also been associated with increased albuminuria in ence of heavy proteinuria was associated with duration
NIDDM. Unfortunately, studies evaluating the roles for of diabetes, severity of diabetes, type of treatment (diet
these factors in predicting progressive microalbuminuria vs. oral antihyperglycemic agents or insulin), and blood
are lacking. pressure [99].
Mortality in NIDDM patients with persistent protein-
Stage IV: Overt nephropathy uria is very high [103]. In diabetic Pima Indians with
Persistent dipstick albuminuria (UAE . 300 mg/24 hr proteinuria, the mean risk of death was 3.5 times greater
or . 500 mg/24 hr urinary protein excretion) defines than in diabetic patients without proteinuria [103]. This
overt nephropathy. It is characterized by a decline in is primarily due to CVD or a combination of CVD and
GFR and increased mortality. In IDDM, GFR decreases renal disease [28, 103].
with stage of overt nephropathy but does not decrease
Stage V: End-stage renal diseasewith microalbuminuria. In contrast, in NIDDM, a decline
in GFR has been noted in microalbuminuric patients Nelson et al reported that in Pima Indians with
[91] and even in older patients without albuminuria [92]. NIDDM, the cumulative incidence of ESRD was 40%
Overt nephropathy has been reported to appear five at 10 years and 61% at 15 years following the onset of
years sooner relative to the time of diagnosis of diabetes proteinuria [13, 44]. This is similar to the 50% incidence
of ESRD after 10 years of proteinuria in IDDM patientsin NIDDM patients compared with IDDM, although this
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Fig. 2. Cumulative incidence of proteinuria in
Japanese patients (s) and Pima Indians (d) with
NIDDM and in two studies of white subjects with
IDDM [Joslin Clinic, Boston (j) and Steno Me-
morial Hospital, Denmark (h)]. The incidence in
patients with NIDDM was higher through 20
years of diabetes than in those with IDDM. Data
are from Knowler and Kunzelman [99].
their lower death rates from CVD [85], the cumulative
incidence of ESRD in this population closely resembles
that of whites with IDDM.
In the vast majority of patients, GFR begins to decline
with the onset of proteinuria. In one study on the natural
course of diabetic nephropathy in IDDM, proteinuria
appeared on average after 17 years, and ESRD appeared
22 years after the onset of diabetes [107]. The rate of
decline in GFR averaged 1 ml/min/month, with 50% of
the patients reaching ESRD seven years after the onset
of proteinuria [108]. Recent reports suggest that the rate
of decline in GFR has slowed in IDDM [106]. This may
reflect more effective interventions.
Among Pima Indians, in whom NIDDM develops at
a younger age than in other populations, the decline in
GFR is similar to that of IDDM (1 ml/min/month from
onset of macroalbuminuria) [109]. Ordonez and Hiatt
noted that once proteinuria occurred, nephropathy pro-Fig. 3. Cumulative incidence of ESRD by duration of proteinuria in
NIDDM and IDDM patients. Data are from Nelson et al [44], Hum- gressed at the same rate in IDDM and NIDDM [110].
phrey et al [105], and Krolewski et al [106]. Symbols are: (d) whites Biesenbach, Janko and Zazgornik examined a popula-with IDDM; (j) Pima Indians with NIDDM; (r) whites with NIDDM.
tion of proteinuric NIDDM patients with an average
initial creatinine clearance (CCr) of 81 6 6 ml/min/1.73
m2 [111]. Patients developed ESRD after a mean of 81
months (range, 40 to 124 months). The average rate ofat the Joslin Clinic. This high incidence of ESRD does
not appear to be unique to the Pima Indians [104], as loss of CCr in NIDDM patients was similar to IDDM. In
patients with NIDDM, the rate of loss of CCr was twofoldthe same has been observed in most studies examining
European and American NIDDM populations. greater in patients with systolic blood pressure (SBP)
more than 160 mm Hg and in smokers. The latter obser-Figure 3 shows the cumulative incidence of ESRD as
a function of duration of proteinuria in Pima Indians vation is in keeping with the risk of albuminuria in smok-
ers with IDDM and NIDDM [112].[44], in whites with NIDDM [105], and in whites with
IDDM [106]. Coronary heart disease is a frequent cause Gall et al examined albuminuric NIDDM patients with
biopsy-proven diabetic glomerulosclerosis [113]. Theof death in older persons with diabetes and proteinuria,
and may account, in part, for the lower incidence of majority (21 of 26) received antihypertensive treatment.
The average rate of decrease of GFR was 5.7 ml/min/ESRD in whites with NIDDM. Because of the relatively
young age at onset of NIDDM in Pima Indians and year. This rate of decline correlated with blood pressure
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Table 2. Comparison of stages of diabetic nephropathy in patients with IDDM and NIDDM
Prevalence of renal involvement
Clinical term Functional/clinical
Stage (onset)e Histologic features features IDDM NIDDM
I. Initial stage Glomerular hypertrophy • ↑ GFR 90–95% 15–45% (hyperfiltration)
(at diagnosis) and increased kidney
volume in IDDM; not 15–20% (MIA)
a constant feature 5–8% (MAA)
in NIDDM. usually normotensive hypertension frequent
II. Early renal involvement GBM thickening, • ↑ GFR 90–95%f ?50%
(1.5–5 years) mesangial expansion usually normal MIA, MAA, and BP may
AER be present
III. Incipienta nephropathy Further GBM thickening • ↑ AER (incidence) 20% 40%
(5–15 years) and mesangial expansion • ↑ AER (progression) 80% 20%
• ↑ BP 25% 70%
IV. Overtb nephropathy Diffuse and/or nodular • Albuminuria (.300 mg/day) 30–40% 30–40%
(10–20 years) glomerulosclerosis • ↑ BP 60–65% 90–100%
• Gradual decrease in GRF in
both IDDM & NIDDM (un-
treated) (5–10 ml/min/year)
V. End-stage renal disease Glomerular closure and • GFR , 15 ml/minc 30–40% 10–35%
(201 years) obsolescence • Retinopathyd 92% 55–65%
• Neuropathyd 83% 82%
• Cardiac diseased 67% 75%
• Vascular diseased 29% 21%
Abbreviations are: MIA, microalbuminuria; MAA, macroalbuminuria; AER, albumin excretion rate.
Data are from references a 75; b 100; c 44, 105, and 106; and d 5.
e Relative to diagnosis of diabetes in IDDM; variable in NIDDM
f Percentage refers to GBM thickening
Table 3. Predictors of nephropathy in NIDDMcontrol and albuminuria. Hasslacher et al found an aver-
Genetic factorsage annual loss of CCr by the Cockroft-Gault formula of
Elevated blood pressure5.3 ml/min/1.73 m2 in NIDDM patients with proteinuria Smoking
followed at the Heidelberg Clinic [114]. Their rate of Hyperglycemia
Family history of nephropathyloss of CCr correlated with postprandial glucose levels. Family history of cardiovascular events
The last finding provides indirect evidence for a role Parental hypertension
Low birth weight?for glycemic control in progression of NIDDM-related
Male gendernephropathy. Advanced age
Overall, the cumulative incidence of ESRD in Microangiopathy (retinopathy)
Macroangiopathy (coronary heart disease, arterioocclusive disease)NIDDM varies between 10% and 35%. The fact that
IDDM may carry a higher odds ratio for the develop-
ment of ESRD [115] does not necessarily imply a more
benign renal prognosis in NIDDM. It may reflect greater
tes obviously are determinants of diabetic renal diseaseheterogeneity of renal risk or greater attrition from car-
(Table 3).diac death prior to the development of ESRD. Further-
more, although proteinuria in NIDDM might appear
Duration of diabetes and agesooner relative to the time of diagnosis of diabetes, the
average rate of loss of GFR appears to be similar both Duration of diabetes was one of the most important
in NIDDM and IDDM. Table 2 compares the five stages risk factors for diabetic nephropathy in four major stud-
in the natural history of diabetic nephropathy in IDDM ies (Fig. 2). The influence of duration was greater than
and NIDDM. that of age, gender, or type of diabetes. In the Rochester,
Minnesota, cohort [28], older age at onset of diabetes
and male gender were risk factors for proteinuria in
RISK FACTORS FOR NEPHROPATHY IN NIDDM NIDDM. Separate analyzes controlling for age indicated
Only 20% to 50% of patients with NIDDM develop no association with duration of NIDDM. When patients
proteinuria after 20 years of diabetes, depending on the with NIDDM were matched for years after diagnosis of
diabetes, patients diagnosed after age 50 had a higherpopulation studied. Therefore, factors other than diabe-
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prevalence (76%) and degree of microalbuminuria than The role of this polymorphism in diabetic nephropathy
remains unclear. Marre et al reported an associationthose diagnosed before age 40 (38%) [116].
between the ACE I/D genotype and renal disease in
Familial and racial factors diabetes, determining the ACE genotype in IDDM pa-
tients with persistent microalbuminuria (30 to 300 mg/Separate inherited risks exist that determine whether
a given individual develops diabetes mellitus and whether 24 hr) or macroalbuminuria (more than 300 mg/24 hr)
[128]. The II genotype was present in 4% of patientshe or she develops diabetic nephropathy in NIDDM
[117]. Pettitt et al found that renal disease clusters in with albuminuria, which was significantly lower than in
control patients (15%). Doria, Warram and KrolewskiPima Indian families with NIDDM [118]. Proteinuria
occurred in 14% of diabetic offspring in whom neither concluded that the ACE I/D genotype in conjunction
with a second ACE gene polymorphism contributed toparent had proteinuria, in 23% of offspring in whom one
diabetic parent had proteinuria, and in 46% of offspring the susceptibility to diabetic nephropathy in white
IDDM individuals [129]. Studies from Denmark [130],in whom both parents had diabetes and proteinuria. Fa-
milial clustering of albuminuria is also apparent in whites Germany [131], and the Netherlands [132], however, re-
ported that the ACE genotype distribution in IDDM or[67] and in African Americans with NIDDM [119]. In
the latter, the risk for developing ESRD was eightfold NIDDM patients with albuminuria more than 30 mg/
day was indistinguishable from that of diabetic patientsgreater if a close relative with NIDDM had ESRD. Fa-
milial clustering of hypertension and CVD in families without albuminuria. A meta-analysis of 11 studies deal-
ing with ACE/ID polymorphisms [133] found no differ-with NIDDM and nephropathy also occurs [119]. Ge-
netic factors and glycemic control may interact in these ence in the distribution of D and I alleles between case
(N 5 562) and control patients (N 5 939). Similar resultsfamilies to heighten the frequency of microalbuminuria
and overt nephropathy. have been obtained in white NIDDM patients with and
without nephropathy [131, 134, 135], although studies inEthnic factors may influence the development of ne-
phropathy in NIDDM. African Americans may be more Japanese NIDDM patients suggest that the D allele may
be a risk factor for nephropathy [135].at risk for ESRD in NIDDM [12, 115]. A greater risk
for NIDDM-associated nephropathy has been reported
ACE gene polymorphism and progressionin Maoris [14], Australian aboriginals [14], and Indian
of nephropathyimmigrants in the United Kingdom [120].
There is no firm basis yet that ACE polymorphisms are
Candidate genes risk factors for the “initiation” of diabetic nephropathy.
However, there is evidence that the RAS may play aBecause high blood pressure and CVD are related to
the risk of nephropathy in NIDDM [43, 121, 122], genes role in its “progression” [136, 137]. Yoshida et al found
a significantly higher incidence of the DD genotype ininvolved in blood pressure regulation and cardiovascular
risk are obvious candidate genes for diabetic nephropa- NIDDM patients with declining renal function [136]. DD
patients had a greater than fourfold risk for progressionthy. These include genes encoding the renin-angiotensin
system (RAS) [123], the sodium-proton exchanger [124], to ESRD. The DD genotype was not present in patients
with overt proteinuria and concurrently stable renaland components of GBM [125].
function, implying that proteinuria in diabetic DD pa-
ACE gene polymorphism and initiation tients is incompatible with preservation of renal function.
of nephropathy Schmidt et al also noted that there was a higher preva-
lence of the DD genotype in NIDDM patients on dialysisThe D (deletion) allele of the ACE gene is character-
ized by higher circulating and tissue levels of ACE, in [138].
contrast to the I (insertion) allele. This may result in
Polymorphism of angiotensinogen and Angiotensinhigher angiotensin (Ang) II concentrations, particularly
receptor genesin tissues in which ACE activity constitutes a rate-lim-
iting step in the RAS cascade. Because Ang II is thought There are no solid data yet linking polymorphisms in
the angiotensinogen gene (M235T) or the type I Ang IIto be involved in the onset and progression of diabetic
renal disease, it is reasonable to categorize this polymor- receptor gene to nephropathy in NIDDM [132, 134, 137].
In one study [139], the authors genotyped for the M235Tphism as a potential determinant of macrovascular and
microvascular diabetic complications. polymorphism in IDDM and NIDDM patients from
Northern Ireland and found a significantly higher angio-Originally, Cambien et al demonstrated that an inser-
tion (I)/deletion (D) polymorphism of the ACE gene tensinogen TT genotype (20%) in IDDM patients with
nephropathy versus IDDM without nephropathy (8%).(ACE/ID) was associated with an increased risk for myo-
cardial infarction in nondiabetic patients [126]. This asso- TT was found in 8% of the general population. There
were no significant differences in the M235T polymor-ciation has been extended to IDDM and NIDDM [127].
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phism in NIDDM patients compared with the general
population. Data from Schmidt et al also revealed no
significant differences in allele frequency for angioten-
sinogen M or T in European NIDDM patients with and
without albuminuria more than 30 mg/24 hr [137].
Sodium/lithium countertransport
Increased red blood cell (RBC) sodium/lithium ex-
change (Na1/Li1), as a surrogate for sodium/proton co-
transport, has been proposed as a genetic marker for
hypertension in nondiabetic patients. Two [140, 141] of
four studies in NIDDM patients [140–143] reported an
increased Na1/Li1 exchange. In the study from Ruther-
ford et al, NIDDM patients with nephropathy had sig-
nificantly reduced Km and Vmax for Na1/Li1 exchange
compared with uncomplicated diabetic and nondiabetic
control patients [141]. Considerable overlap existed be-
tween the different groups, and the predictive power of
Na1/Li1 exchanger activity was dependent on long-term
glycemic control [144]. Several nongenetic factors also
influence Na1/Li1 exchanger activity, including hyperlip-
idemia, insulin resistance, hypokalemia, oral contracep-
tive use, and membrane fluidity [145]. The first two are
often associated with NIDDM. A propensity to hyper-
tension may also be part of the genetic predisposition
to nephropathy in NIDDM [142]. Pietruck et al recently
described enhanced G-protein coupling in B lymphoblast
cell lines of IDDM patients with diabetic nephropathy
[146]. In ongoing studies, the G-protein abnormality has
been examined in conjunction with NIDDM-related re-
nal and cardiovascular complications. Preliminary results Fig. 4. Prediabetic systolic blood pressure and prevalence of A/C ratio
are compatible with the idea that these changes are re- (g/g) of greater than 0.1 in 356 Pima Indians (A). Data are from Viberti
and Earle [149]. Prevalence of abnormal albumin exertion [albuminlated to Na1-H1 exchanger abnormality.
(mg)-to-creatinine (g) ratio 5 100] after the diagnosis of diabetes by
prediabetic mean blood pressure (B). Data are from Nelson et al [121].Hypertension
The relationship between blood pressure and renal
disease is problematic because elevated blood pressure
may be a cause or consequence of renal disease. The true for NIDDM. Up to the time of diagnosis of NIDDM,
many patients are hypertensive even without albumin-deleterious effects of systemic blood pressure on glomer-
uli were reported more than 20 years ago in a patient with uria. This is possibly due to the fact [150] that patients
genetically predisposed to NIDDM may have been hy-NIDDM and unilateral renal artery stenosis in whom
nodular diabetic glomerulosclerosis was present in the pertensive for years prior to the onset of diabetes as part
of a metabolic syndrome [151] characterized by insulinnonischemic kidney [147]. Because abnormal metabolic
conditions would affect both kidneys, it seems likely resistance, obesity, dyslipidemia, and hypertension.
Hypertension before the onset of diabetes in Pimathat the stenosis protected the ipsilateral kidney. Animal
studies also suggest that hemodynamic changes may in- Indians conferred a greater risk of postdiabetic renal dis-
ease [149]. Similarly, hypertension prior to the diagnosisfluence diabetic nephropathy. Uninephrectomy in ani-
mals, leading to hyperfiltration in the remaining kidney, of diabetes was associated with an abnormal UAE after
the diagnosis of NIDDM [121] (Fig. 4). Higher predia-markedly accelerates experimental diabetic nephropathy
[148]. betic blood pressure could reflect susceptibility to renal
disease in the presence of diabetes or, alternatively, beHypertension appears to play a role in the nephropa-
thy of NIDDM [121, 149]. The relationship between hy- a risk factor for more severe NIDDM [152]. Recent studies
compared offspring of NIDDM parents with or withoutpertension and renal disease is different in IDDM and
NIDDM. Although in IDDM the presence of hyperten- diabetic nephropathy and found that in nonobese adult
individuals, ambulatory SBP averaged 8 mm Hg highersion usually indicates renal involvement, the same is not
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Table 4. Hypertension as a predictor of nephropathy in type II diabetes during the preproteinuric phase
Median (range)
Patients
Post-prandial glucose Blood pressure
Patients mg/dl mmHg Normotensive Hypertensive
Developing persistent proteinuria (N 5 63) 208 (130–295) 164 (105–215) a 19/63 (30%) c 44/63 (70%)
87 (70–106) b
Not developing persistent proteinuria (N 5 63) 199 (104–272) 149 (122–183) a 36/63 (57%) 27/63 (43%)
84 (68–97) b
Modified, with permission, from Hasslacher [153].
a Systolic blood pressure
b Diastolic blood pressure
c P , 0.05
in offspring of parents with diabetic nephropathy [122].
Hasslacher et al found that diabetic patients who devel-
oped proteinuria later were more frequently hyperten-
sive in the preproteinuric state than patients who failed
to develop proteinuria (Table 4) [153].
The finding of a high prevalence of hypertension in
NIDDM is not a new one. Pell and D’Alonzo reported
an increased frequency of hypertension in NIDDM in
1967 [154]. Their case-control study demonstrated a 50%
greater prevalence of hypertension in NIDDM com-
pared with matched nondiabetic controls. The increased
frequency of hypertension was independent of obesity
and occurred more commonly in patients with NIDDM
even in the absence of proteinuria or renal disease. Ritz
et al noted that up to 70% of NIDDM patients without
persistent proteinuria were hypertensive according to
the World Health Organization definition (Fig. 5) [155].
More recently, they used ambulatory blood pressure
monitoring in 85 newly diagnosed NIDDM patients.
Sixty percent of these patients were hypertensive, and
61% had an attenuated nocturnal decrease in blood pres-
sure. A normal blood pressure profile was found in only
21% of the patients [43]. Hypertension is thus a feature
Fig. 5. Prevalence of hypertension by the World Health Organizationof early NIDDM, acting as a risk factor for nephropathy
criteria in type I (IDDM; A) and type II diabetes (NIDDM; B) inand a contributor to progression. Several studies have
different stages of diabetic nephropathy. Data are from Ritz et al [155].
noted a more rapid decline in GFR in hypertensive com-
pared with normotensive NIDDM patients. Biesenbach
et al also found a more rapid progression at SBP more
than 160 mm Hg [111], and Perneger et al noted that vascular volume, cardiac output, and stroke volume con-
adjusting for hypertension decreased the odds ratio for tinue to be considered as pathogenetic mechanisms lead-
developing ESRD in NIDDM [115].
ing to obesity-related hypertension [156]. In addition to
It should be pointed out that obesity, in and by itself,
salt-dependent hypertension, obesity may be associatedis associated with abnormal renal physiology, which is
with interstitial and glomerular disease in the absencehighly relevant to any discussion of NIDDM. Patients
of hyperglycemia and hyperfiltration. This must contrib-with upper-body obesity have a high incidence of hyper-
ute to the fact that the vasculopathies of IDDM andtension. Several recent studies cast doubt on the idea that
NIDDM are not quite the same. In the same vein, theinsulin resistance and hyperinsulinemia are the initial
glomerular pathologies of the two states are different,triggers of the cascade of defective mechanisms de-
and the tubulointerstitial changes of NIDDM are morescribed in obesity-related hypertension. However, insu-
prominent in the early stages of the disease, suggestivelin resistance enhanced activity of both the RAS and
that different forces are at work, even if the outcome issympathetic nervous systems, a decrease in the secretory
response of atrial natriuretic factors, and increased intra- the same.
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Hyperglycemia Smoking
Smoking, a strong predictor of renal risk in IDDMHyperglycemia appears to be important for the devel-
[168], is also associated with progression in NIDDMopment of proteinuria in NIDDM. Ballard et al high-
[169]. It has also been noted that NIDDM patients withlighted this association using a proportional hazards anal-
microalbuminuria were more frequently smokers thanysis to define significant predictors of proteinuria in
nonsmokers. Olivarius et al, examining male patientsNIDDM patients [28]. Hyperglycemia was a significant
with newly diagnosed NIDDM, found that heavy albu-risk factor, especially in younger (.60 years) diabetic
minuria (that is, A/C ratio more than 20 mg/mmol) waspatients, perhaps because of a competing risk of death
more common in smokers (8.2%) and former smokersin older (,60 years) patients.
(7.3%) than in nonsmokers (2.1%) [112]. It is of interestVasquez et al noted a reduction in proteinuria when
that smoking is also an independent risk factor for albu-NIDDM patients were placed on a hypocaloric diet de-
minuria in patients with essential hypertension [170].creasing hyperglycemia [157]. However, the effect of the
Tobacco smoking can cause vasoconstriction, impaireddietary intervention must also be considered as a con-
platelet function, and abnormal regulation of coagula-founding variable. Insulin resistance, another aspect of
tion and blood pressure [171], accelerating the processesNIDDM, precedes the onset of microalbuminuria in
of vascular damage that often affect diabetic patients
NIDDM [158], and greater degrees of insulin resistance
[172].
are evident when UAE is elevated in NIDDM [159]. It
has been suggested that hyperglycemia and hyperinsulin-
PATHOGENESISemia in the prediabetic state may contribute to microal-
buminuria in NIDDM [160]. Further evidence for a role Intrarenal determinants of elevated GFR and their
of hyperglycemia in the development of proteinuria in relationship to the glomerulosclerosis have been tested
NIDDM comes from the Kumamoto study [161], which extensively in experimental models of diabetes. In-
documented significantly less nephropathy in NIDDM creased RPF and glomerular capillary pressure mediate
hyperfiltration. Glomerular hypertension (independentpatients with intensive insulin treatment.
of systemic hypertension) may be an important factorThe role of hyperglycemia in the progression of
in the initiation and progression of diabetic nephropathyNIDDM-related nephropathy is not clear. Many of the
[173]. A reduction in intrarenal vascular resistance favorsaforementioned studies suggested that poor glycemic
the occurrence of glomerular hypertension, and this in-control was associated with an increasing rate of decline
creases shear stress. Damage to endothelial and epithe-in GFR. Certainly, the pathogenesis of hypertension in
lial cells will ensue and disrupt the filtration barrier.NIDDM may be related in part to hyperglycemia, so-
That hyperfiltration is not the only factor leading todium retention, and insulin resistance [162]. The Appro-
renal disease in NIDDM is demonstrated again in datapriate Blood Pressure Control in Diabetes Trial analyzed
from Pima Indians. Diabetic Pima Indians have elevatedglycemic control and progression in NIDDM [102]. Mean
GFR at early stages of NIDDM. However, baseline GFRfasting blood glucose and HbA1C values were lower in
was not predictive of increasing UAE nor declining GFRnormoalbuminuric patients compared with microalbumi-
during a four-year follow-up, suggesting that other fac-nuric patients or patients with overt nephropathy.
tors contributed to the progression of nephropathy [109].The association between glycemic control and
Certainly, the abnormal biochemical milieu is important.NIDDM-associated nephropathy was further substanti-
Elevated ambient glucose concentrations alter many cel-
ated in the Oklahoma Indian Diabetes Study [163]. Indi- lular functions relevant to diabetic nephropathy. They
viduals in this study with a fasting blood glucose more stimulate the sorbitol pathway [174], induce advanced
than 200 mg/dl had a 2.9-fold increased risk of ESRD glycation end-product formation [175], disrupt synthesis
compared with patients with normal fasting glucose val- of glycosaminoglycans [176], and activate protein kinase
ues. This same increased risk for ESRD is evident in C [177].
Pima Indians [164]. This may not be a universal associa- Some of these changes may affect the GBM. Diabetic
tion, as studies in African Americans with NIDDM failed nephropathy is characterized by GBM thickening and
to demonstrate a direct link between hyperglycemia and mesangial expansion, primarily as a result of extracellu-
nephropathy [165, 166]. Nevertheless, the Diabetes Con- lar matrix protein accumulation. The extent of mesangial
trol and Complication Trial (DCCT) confirmed a role expansion correlates with the clinical disease state. Quan-
for hyperglycemia in renal disease in IDDM patients titative studies have demonstrated that the early appear-
[167], and a similar role for glycemic control in NIDDM ance of microalbuminuria is closely correlated with mes-
is likely. Hopefully, data from the United Kingdom Pro- angial matrix expansion and GBM thickness [178].
spective Diabetes Study (UKPDS) in 1998 will provide Experimental models have shed light on some of the
mechanisms leading to the development of diabetic ne-an answer to this question.
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phropathy. Investigators, however, have focused on insu- nephropathy have retinopathy [80, 113, 190–192]. In the
study of Gall et al, one third of NIDDM patients withlinopenic models (analogous to IDDM), rather than
hyperinsulinemic models (analogous to NIDDM). Glo- biopsy-proven nephropathy did not have evidence of
retinopathy [113]. Parving et al noted that 41% of pro-merular lesions occur in some models of NIDDM but
not in others [179]. Mesangial expansion and GBM thick- teinuric NIDDM patients with nephropathy lacked reti-
nopathy [190] compared with 60% or more of proteinuricening are found in many, but nodular lesions are found
in only a few. Animals in these models do not develop NIDDM patients in studies from Marshall and Alberti
[191] and Schmitz and Vaeth [80].renal failure. For example, Zucker diabetic fatty rats
have hyperglycemia, hyperinsulinemia, and hyperlipid- In the study by Parving, glomerulosclerosis was evi-
dent in all albuminuric patients with retinopathy. Theemia and develop progressive albuminuria. However,
they develop hydronephrosis and interstitial disease, not specificity of retinopathy for the presence of nephropa-
thy was 100%, whereas the sensitivity was 40%. Theglomerular disease [180].
Spontaneous focal segmental glomerulosclerosis has majority of patients with diabetic renal disease have reti-
nopathy, however, the reverse is not true. The percent-been observed in autosomal recessive obese Zucker rats
[181]. Obese rats demonstrate glucose intolerance and age of NIDDM patients with concurrent retinopathy and
nephropathy is unknown. The incidence of retinal dis-insulin resistance [182], preceding albuminuria and renal
injury. Glomerular hemodynamics are not significantly ease is greater than nephropathy. This discrepancy may
reflect a greater sensitivity of fundoscopic examinationdifferent between young obese Zucker rats and their
lean litter mates [183], a finding of interest in view of for the presence of microangiopathy compared with the
clinical diagnosis of nephropathy.abnormal GFR in insulinopenic models of diabetes.
Diabetic nephropathy is strongly influenced by genetic Specificity of albuminuria in NIDDM. Biopsy studies
suggest that 25% to 50% of patients with NIDDM have abackground. Wistar fatty rats (fa/fa), derived from cross-
ing Zucker with Wistar-Kyoto rats, are obese with hyper- glomerular lesions unrelated to or in addition to diabetic
nephropathy [113, 190, 192–194] (Table 5). Nondiabeticinsulinemia, glucose intolerance, hyperlipidemia, hyper-
phagia, hyperglycemia, polydipsia, and glycosuria [184]. renal disease in IDDM is much less prevalent (5%).
Recruitment bias and lack of uniform criteria for biopsySodium excretion is impaired, and the natriuretic effect
of atrial natriuretic peptide [185] is reduced in these interpretation may have overestimated nondiabetic ne-
phropathy in NIDDM. Schwartz et al found nondiabeticanimals.
renal disease in only 3 of 32 NIDDM patients [192].
Hyperlipidemia Parving et al found a high incidence (77%) of diffuse or
nodular diabetic glomerulosclerosis in 27 of 35 NIDDMDyslipidemia could play a role in the development
of diabetic glomerular lesions. Treatment with clofibric patients with persistent albuminuria [190]. Similarly, Lip-
kin et al noted that 25 of 82 patients had nondiabeticacid and mevinolin, structurally unrelated lipid-lowering
agents, altered the appearance of glomerular lesions [186] renal lesions.
In another study, biopsy specimens from 52 protein-in experimental studies. It is currently unknown whether
the same is true for NIDDM. There has been much uric NIDDM patients were examined [193]. Diffuse or
global glomerulosclerosis, glomerular hypertrophy, andexcitement concerning an observation [187] that found
that four weeks of pravastatin treatment reduced pro- arteriolar hyalinosis were present in 19 patients. Sixteen
patients had nonspecific glomerular changes. Exudativeteinuria in hypercholesterolemic patients with NIDDM.
lesions (fibrin caps or capsular drops) and GBM thick-
Nondiabetic renal disease in NIDDM ening were also present. The remaining 17 patients had
a form of glomerular disease superimposed on diabeticThe diagnosis of diabetic nephropathy is almost always
based on clinical grounds. The diagnosis is supported glomerulosclerosis. Thus, nondiabetic renal disease is
present with some variability in NIDDM.by a long history of diabetes, evidence of target organ
damage, and proteinuria preceding azotemia. The valid- Because proteinuria in NIDDM is less specific than
in IDDM, a lack of retinopathy, autonomic neuropathy,ity of this clinical approach is well established in IDDM
[188, 189] but not in NIDDM. or a short interval between onset of diabetes (less than
5 years) and proteinuria raises the possibility of a nondia-The renal-retinal relationship in NIDDM. There is a
dearth of information on retinopathy in NIDDM pa- betic renal lesion [190, 195]. These findings warrant
strong consideration for renal biopsy (Table 6). Manytients with renal disease. The available studies are flawed
by a lack of uniform methodology, absence of fluores- studies have documented a primary glomerulonephritis,
particularly membranous or IgA glomerulonephritis incence angiography, etc. Some clinically useful informa-
tion, however, can be drawn from these studies. Ninety patients with NIDDM [190, 195, 196]. However, super-
imposed glomerulonephritis in NIDDM is not frequentto 95% of IDDM patients with diabetic nephropathy
have retinopathy. Forty to 75% of NIDDM patients with in systematic postmortem or biopsy studies (for example,
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Table 5. Diabetic and non-diabetic renal disease in patients with NIDDM
Renal histology
No. of
Author [reference] patients Nature of study and/or reason for biopsy DGS DGS & other Other
Amoah [195] 60 Retrospective analysis, evaluation of renal dysfunction 72% 7% 22%
Parving [190] 35 Evaluation of albuminuria 77% 23%
Gambara [193] 52 Evaluation of albuminuria and renal dysfunction 36% 33% 30%
Fabre [94] 50 Natural history, retrospective 82% 18%
Waldherr [197] 205 Autopsy 80%
Lipkin [194] 82 Evaluation of albuminuria 61% 9% 30%
Schwartz [192] 32 Evaluation of albuminuria 91% 9%
DGS is diabetic glomerulosclerosis.
Table 6. Findings suggestive of non-diabetic renal disease in NIDDM Table 7. Strategies in the prevention of progression of nephropathy
in type II diabetes
• Proteinuria without retinopathy
• Overt nephropathy with NIDDM ,5 years Antihypertensive treatment
Glycemic control• Renal failure without significant proteinuria
• Sudden onset nephrotic syndrome Discontinuation of smoking
Dietary protein restriction?• Rapid decline in GFR (.1 ml/min/month)
• Persistent gross and microhematuria unexplained by urologic Treatment of hyperlipidemia
Avoidance of nephrotoxinspathology
• RBC casts Radiocontrast agents: avoid unless absolutely indicated, modify dose,
non-ionic agents (nephropathy with renal failure)
Waldherr et al [197] and Pinel et al [198]), and its occur-
nary excretion rate of prostaglandin F1a and 12-HETE inrence may simply reflect coincidence.
NIDDM patients with hyporeninemic-hypoaldosteronism
Microhematuria in NIDDM and in control patients [203]. Excretion of 12-HETE was
increased in the diabetic patients in general. Moreover,Microscopic hematuria with or without RBC casts has
the NIDDM patients with hyporeninemic-hypoaldoste-been reported in diabetic nephropathy [199]. One survey
ronism had a marked reduction in prostaglandin F1aof 30 patients with diabetic nephropathy revealed hema-
excretion despite increased 12-HETE excretion. Thisturia in 30% and RBC casts in 13%. In a separate group,
may be one mechanism contributing to hyperkalemia inrenal biopsy tissue from eight diabetic patients with RBC
NIDDM.casts was examined. Five individuals had only diabetic
nephropathy, and three patients had a disease other than
diabetic nephropathy. Other series have suggested that INTERVENTIONS IN NIDDM
a large fraction of diabetic patients with hematuria have
Diabetes is a costly illness with frightening morbiditysuperimposed glomerulonephritis [200]. Consequently,
and premature mortality as illustrated by the fact thathematuria, and particularly RBC casts, requires further
NIDDM patient survival on dialysis is equivalent to thatevaluation.
of patients with gastric carcinoma. The magnitude of the
problem and its economic impact have led to efforts toHyperkalemia and hyporeninemic-hypoaldosteronism
identify preventive and therapeutic options. It is logicalAngiotensin-converting enzyme inhibitors are now
to assume that maintaining euglycemia, stopping smok-standard medications for diabetic patients with protein-
ing, and controlling blood pressure may prevent the on-uria. Hyperkalemia has become more problematic with
set or slow progression of diabetic nephropathy and maytheir increased use. Some patients may demonstrate a
reduce extrarenal injury (Table 7).voltage-dependent distal renal tubular acidosis with nor-
mal or increased aldosterone levels and a hyperchloremic
Blood pressure controlmetabolic acidosis with sodium wasting and increased
Consensus statements have emphasized the impor-serum potassium [201]. More commonly, patients will
tance of antihypertensive therapy in preventing the de-have hyporeninemic-hypoaldosteronism as the cause of
velopment and progression of diabetic nephropathy [66,their hyperkalemia [202]. Recent studies suggest that
204]. The kidney appears to be injured by elevated blooddeficiency in prostacyclin production and a concomitant
pressure, including even values that are normotensiveincrease in 12-hydroxyeicosatetraenoic acid (12-HETE)
according to World Health Organization or Joint Na-may underlie hyporeninemic-hypoaldosteronism and hy-
perkalemia in NIDDM. Antonipillai et al studied the uri- tional Commission criteria in diabetic and nondiabetic
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renal disease [205]. Consequently, recommendations in-
clude treating even normotensive IDDM and NIDDM
patients once microalbuminuria is present. Evidence for
a beneficial effect of this strategy in NIDDM is less
conclusive than in IDDM [206]. However, this approach
seems reasonable in an effort to limit renal damage [101,
207].
Practical points concerning management of hyperten-
sion in NIDDM include the following:
(I) Salt balance. Exchangeable sodium is increased in
IDDM and NIDDM patients [208]. Blood pressure is
frequently salt sensitive even in nonalbuminuric diabetic Fig. 6. Renal end point (doubling of serum creatinine or renal death)
in 21 NIDDM patients in the AIPRI. Six patients were on the ACEpatients [209]. Reducing dietary sodium intake and di-
inhibitor benazepril, and 15 patients were on placebo. Data are fromuretic treatment are therefore logical therapeutic ap- Maschio et al [230].
proaches. It is widely believed that diuretic monotherapy
is not advisable [210]. However, this concern may not
apply when low doses of diuretics are used [211]. The
adverse metabolic effects of diuretic monotherapy may targeted [66, 204, 205]. The selection of antihypertensive
be prevented by concomitant use of ACE inhibitors. agents is also important because of the renoprotective
The importance of reversing sodium retention (and effect of ACE inhibitors [220, 221] and, less uniformly,
extracellular volume expansion) is illustrated by the ob- that of CCBs [222].
servation that reduction of proteinuria was most pro- (IIa) ACE inhibitors and AT1 blockers. Two meta-
nounced in studies using ACE inhibitors in which the analyses [220, 221] concluded that ACE inhibitors were
highest doses of diuretics were given [212]. The antipro- renoprotective in diabetic patients. In addition, prospec-
teinuric and antihypertensive effects of ACE inhibitors tive placebo-controlled trials in normotensive microal-
are amplified by sodium restriction [213, 214], as is the buminuric NIDDM have shown a diminished rate of
antiproteinuric effect of calcium channel blockers (CCBs) progression of proteinuria with ACE-inhibitor treatment
[215]. Control of hypervolemia is particularly important [223]. Captopril has been administered to normoalbumi-
to prevent nighttime elevation in blood pressure [216]. nuric, normotensive NIDDM patients in small short-
Diuretic treatment is frequently neglected in the anti- term studies. ACE inhibition appeared to prevent even
hypertensive management of NIDDM patients, although the onset of microalbuminuria [224], but this will require
one obviously has to avoid the risk of hypovolemia. In further analysis. There is no doubt that in hypertensive
the initial stages of diabetic nephropathy, thiazides are microalbuminuric NIDDM patients, ACE inhibitors di-
usually sufficient, but with impaired renal function, loop
minish the UAE [219, 223, 225–227] or at least prevent
diuretics are necessary. Uncontrolled clinical experience
an increase in UAE [60, 226]. In general, ACE inhibitorsindicates that in NIDDM, the combination of loop di-
are relatively safe despite risks of unrecognized renaluretics and thiazides increases diuretic potency as it does
artery stenosis and hyperkalemia in NIDDM. It is impor-in nondiabetic renal disease [217, 218]. Because of the
tant, too, that ACE inhibitors improve glucose uptakehigh prevalence of hyporeninemic hypoaldosteronism,
in peripheral tissue in NIDDM patients [228] with bene-potassium-sparing diuretics must be used more cau-
ficial effects on glycemic control, although this maytiously, particularly when patients are treated with ACE
slightly increase the risk of hypoglycemia.inhibitors. These drugs are contraindicated when serum
Angiotensin-converting enzyme inhibition is effectivecreatinine is elevated.
in reducing the increase in SCr [223] or measured loss of(II) Antihypertensive medication. Antihypertensive
GFR [222] in diabetics and may even increase GFRtreatment studies differ with respect to endpoints: pro-
[229]. The small subgroup of NIDDM patients in theteinuria or loss of GFR in NIDDM. Studies using preven-
Angiontensin-Converting-Enzyme Inhibition in Pro-tion or modification of structural lesions as endpoints are
gressive Renal Insufficiency Study [230] showed possiblenot available. Studies also differ with respect to patient
long-term benefits (Fig. 6). Nevertheless, no prospectiverecruitment, blood pressure measurement, duration of
controlled study has documented a benefit from ACEobservation, and goals of therapy. Despite these caveats,
inhibitors on definite endpoints in NIDDM patients withthere is general agreement that lowering blood pressure
renal failure. In general, the ACE inhibitors’ antiprotein-is important regardless of the agent used. The most sig-
uric effect is superior to diuretics, b blockers and short-nificant decrease in albuminuria occurred in studies with
acting CCB. Information is currently not available onthe largest reductions in blood pressure [212, 219]. Blood
pressure values in the low to normal range should be AT1 blockers in NIDDM, but two major prospective
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zem [222] to an extent similar to that noted with ACE
inhibitors [237, 238]. In NIDDM patients with overt ne-
phropathy, a comparison between nifedipine and enala-
pril showed different effects on CCr and proteinuria de-
spite similar degrees of blood pressure control. However,
a recent comparison of cilazapril and amlodipine in hy-
pertensive NIDDM patients using Cr51-EDTA clearance
found similar efficacy for cilazapril and amlodipine in
delaying the slope of GFR decline at blood pressure
values of less than 140/85 mm Hg. This is in agreement
with Bakris et al’s recent finding that lisinopril and nondi-
hydropyridine CCB (verapamil or diltiazem) were supe-
rior to atenolol in attenuating the rate of decline of CCr
and in reducing proteinuria in NIDDM [222].
(IIc) Combination ACE inhibitors and CCB. Several
authors have suggested that CCB and ACE inhibitor
used together would be superior to monotherapy with
either drug [231, 239]. When nonhypotensive doses of
verapamil and the ACE inhibitor, trandolapril, were ad-Fig. 7. Renal end point (loss of 40% of initial GFR) as a function of
ministered together in spontaneously hypertensive stroke-diastolic blood pressure in 158 patients with diabetic nephropathy.
Comparison of patients with diastolic blood pressure of 85 mm Hg prone (SHR-sp) rats, less proteinuria and glomeruloscle-
(upper line) or more and less than 85 mm Hg (lower line). P , 0.001. rosis were noted than with either drug alone.Data are from Bjorck [212].
(III) Practical points. Atherosclerotic cerebrovascular
disease should be excluded before blood pressure is low-
ered. Cerebral autoregulation is impaired in elderly hy-
pertensive individuals with NIDDM, and rapid loweringtrials are currently underway to assess their effects on
NIDDM-related nephropathy in NIDDM. of blood pressure poses the risk of cerebral underperfu-
sion. Thus, it is advisable to choose a low initial medica-Angiotensin-converting enzyme inhibitors progres-
sively lose their antiproteinuric advantage over other tion dose that can be increased gradually.
Coronary heart disease also is frequent in NIDDM,agents as blood pressure control increases [221]. Analysis
of an extension of the captopril trial in IDDM [206] leading to consideration of the J-curve phenomenon
[240]. It has been argued that coronary oxygen extractionshowed that the event rate (renal end points) between
the ACE inhibitor and the placebo arms became identi- is maximal already under normal conditions so that low-
ering perfusion pressure below 85 mm Hg diastolic BPcal once treated blood pressure values were less than
95 mm Hg mean arterial pressure (E. Lewis, personal will lead to cardiac ischemia. However, Fletcher and
Bulpitt concluded that cardiac mortality was higher evencommunication). The benefit of aggressive blood pres-
sure control was also shown by Bjorck [212], as signifi- in the placebo arm of trials [241]. Hence, a low diastolic
blood pressure may be no more than a marker of a sickcantly less renal endpoints were observed when diastolic
blood pressure was less than 85 mm Hg (Fig. 7). patient with a high risk to die. In the Modification of
Diet in Renal Disease Trial, there was no evidence of(IIb) Calcium channel blockers (CCBs). CCBs inhibit
vasoconstrictive, hypertrophic, and hyperplastic effects a J-curve phenomenon [242]. This is plausible because
reducing blood pressure decreases afterload and wallof Ang II through blockade of postreceptor calcium-
dependent signaling events [231]. CCBs differ with re- stress. Nevertheless, cardiac ischemia may develop in
individuals with severe coronary artery disease. Suchspect to interactions with voltage-gated L channels, dura-
tion of action, and activation of the sympathetic nervous patients must be carefully monitored during treatment.
Antihypertensive therapy has several uses in NIDDMsystem complicating a generalized assessment of their
efficacy in NIDDM [229, 232]. ACE inhibitors have been in limiting end-organ renal and cardiovascular disease.
Beta blockers have been grossly underused in dialyzedcompared with nifedipine, nitrendipine, or amlodipine
in microalbuminuric NIDDM patients. ACE inhibitors NIDDM patients with coronary heart disease [243]. Car-
diac death rates in NIDDM patients on dialysis not re-were superior when UAE was used as a surrogate end-
point [219, 232–235]. In other studies, ACE inhibitors ceiving b blockers approached 30%. As such, the cardiac
benefit derived from b blockade may be significant inhave also proven more beneficial than CCB with respect
to UAE [222, 236]. The rationale for CCB use comes NIDDM patients [244].
Orthostatic hypotension is frequent in NIDDM pa-from data in IDDM patients that demonstrated a signifi-
cant lowering of albuminuria with verapamil and diltia- tients with autonomic neuropathy. It poses complex
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problems, as it has been associated with increased mor- may obviate the need for intensive insulin treatment
early in NIDDM in the future and will hopefully improvetality. The risk of hypotension is increased by aggressive
diuretic treatment. It is therefore useful to give a major renal outcomes. Interestingly, in the nine-year UKPDS
update, metformin, alone or combined with insulin orproportion of antihypertensive medication at bedtime to
avoid nighttime hypertension and pronounced daytime sulfonylureas, was associated with less weight gain than
sulfonylurea or insulin treatment alone [248]. Metforminhypotension.
appears to be a good choice for the treatment of obese
Glycemic control NIDDM patients as long as renal function is normal. A
recent study that compared metformin and glyburideThe DCCT in IDDM patients suggested that rigorous
glycemic control interfered with the onset of diabetic demonstrated equivalent glycemic control for each; how-
ever, metformin did so without increasing body weightnephropathy, that is, the development of microalbumi-
nuria [167]. Data from renal transplant patients also sup- [236].
port the conclusion that glycemic control can affect dia-
Recommendations about intensive glycemic controlbetic nephropathy. Barbosa et al randomized 48 diabetic
in NIDDMrenal transplant recipients to maximal or standard glu-
cose control and assessed renal pathology by biopsy Glycemic control in NIDDM should be taken as seri-
ously as in IDDM [251]. We recommend target levels[245]. There was a significant increase in mesangial ma-
trix expansion, arteriolar hyalinosis, and GBM widening of glucose control as shown in Figure 8, but the goals
and methods of treatment should be individualized. Ag-in standard therapy patients compared with the maximal
control group. gressive glycemic control may be inappropriate in certain
patients, for example, the aged, those with dementia,Normoglycemia in NIDDM appears to reduce or re-
tard microvascular or macrovascular complications. A those with advanced renal failure, and those with ad-
vanced cardiovascular or cerebrovascular disease.six-year prospective study from Japan evaluated inten-
sive glycemic control (HbA1C levels 7.1%) in NIDDM
Protein restrictionpatients [161]. Patients were separated into a primary
prevention cohort (retinopathy and microalbuminuria Several studies have suggested that protein restriction
can attenuate the evolution of nephropathy in IDDM.not present) and a secondary intervention cohort (pa-
tients with mild retinopathy and microalbuminuria). The Raal et al prospectively followed two well-matched co-
horts for six months on different diets [252]. Patientspercentage of patients developing nephropathy in the
prevention cohort was 8% in the intensive group versus who received moderate protein restriction (0.8 g/kg/day)
had a marked decrease in proteinuria and stabilized their28% in the conventional (HbA1c levels 9.4%) group. In
the intensive control cohort, 12% of patients progressed GFR, in contrast to the patients who received the un-
restricted diet (more than 1.6 g/kg/day). Dullaart et alto nephropathy versus 28% in the conventional group.
The Kumamoto study also suggested that glycemic con- also noted that dietary protein restriction in diabetic
patients with albuminuria reduced the degree of albu-trol may affect the development and progression of mi-
croangiopathy in NIDDM. It is of interest that poor minuria [253].
Few studies have focused on protein restriction in pa-predialysis glycemic control is a predictor of morbidity
on maintenance hemodialysis [246]. Not surprising is the tients with NIDDM. Interestingly, an epidemiologic analy-
sis of a cohort in the San Antonio Heart Study deter-view of the striking impact of glycemia on cardiovascular
survival in NIDDM with cardiac disease [247]. The mined that high protein intake was not a risk factor for
proteinuria in patients with NIDDM [254]. However, in aUKPDS, a large prospective trial evaluating glucose con-
trol in newly diagnosed NIDDM patients, will hopefully randomized crossover trial [255], moderate protein intake
(0.8 g/kg/day) was compared with a high-protein diet (2.0settle the question of glycemic control in NIDDM [248].
Intensive insulin therapy is not without potential ad- g/kg/day) to evaluate its effects on renal function and
glycemic control. The moderate protein diet was associ-verse consequences. Several studies have demonstrated
a paradoxical risk of progression and albuminuria in ated with improvements in GFR and less proteinuria.
Despite the aforementioned data, the findings frompatients treated with insulin [44, 102]. Patients with ne-
phropathy demonstrate insulin resistance more so than the largest trial to date examining dietary protein restric-
tion and progression of renal disease, the Modificationpatients without nephropathy. A pilot study examining
intensive insulin therapy in NIDDM patients who failed of Diet in Renal Disease Study failed to demonstrate
an unequivocal benefit of protein restriction in mostlyoral agents found that these patients were well controlled
on insulin with little weight gain [249]. It has been sug- nondiabetic patients with renal failure [256]. Certainly,
catabolic patients with advanced diabetic nephropathygested that improving insulin resistance without inten-
sive insulin therapy would be ideal [16]. Medications approaching ESRD may be at risk for malnutrition [257].
Based on the evidence in IDDM [258], however, it issuch as metformin [248] and thiozolidinediones [250]
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Fig. 8. Algorithm for prevention of nephropathy or progressive renal disease in patients with NIDDM. Data are from the Ad Hoc Committee
for the Council on Diabetes Mellitus of the National Kidney Foundation [66], the American Diabetes Association [304], and the Forum One of
the Fifth Regenstrief Conference (†) [251]. (††) Other ACE inhibitors may also be appropriate.
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reasonable to recommend a dietary protein intake of 0.75 ering have been carried out in NIDDM [275]. There is
a consensus that in NIDDM patients with no other riskto 0.85 g/kg/day in early stages of diabetic nephropathy.
factors, pharmacological lipid lowering should be consid-
ered if LDL or triglycerides (TG) remain in the high-
RISK FACTOR INTERVENTIONS
risk range [LDL-cholesterol (LDL-C) 160 mg/dl, TG
Lipid disorders greater than 400 mg/dl] [276, 277]. Target levels should
be LDL-C 130 mg/dl, TG less than 200 mg/dl, and inCardiovascular risk is increased by a factor of approxi-
mately 3 in NIDDM [259], and this increase is particu- patients with cardiac risk factors, for example, hyperten-
sion, smoking, family history of premature CVD or evi-larly marked in the presence of proteinuria [103]. Indeed,
50% to 70% of NIDDM patients die in the preterminal dence of microvascular disease, treatment should be
started at even lower concentrations and lower targetsstage of renal failure, mainly from CVD [4].
Cardiovascular disease in NIDDM is excessive even should be aimed for (that is, LDL-C 100 mg/dl and TG ,
150 mg/dl). Given the high cardiovascular risk in NIDDMin nonproteinuric patients [260]. Proteinuria increases
the risk [103]. Dyslipidemia appears to be a primary [259], it is appropriate to lower plasma lipid concentra-
tions in all NIDDM patients with renal involvement andabnormality in NIDDM and is demonstrable even in
prediabetic patients and in individuals with a genetic aim for LDL-C of less than 100 mg/dl [277].
Fibric-acid derivatives have been studied in NIDDMpredisposition to NIDDM [261]. These patients have
elevated total cholesterol and very low-density lipopro- patients with diabetic dyslipidemia, but in patients with
renal involvement, these drugs can have significant unto-tein (VLDL) triglycerides and low high-density lipopro-
tein cholesterol, whereas LDL cholesterol is usually nor- ward effects. HMG-CoA reductase inhibitors are highly
effective in lowering cholesterol in NIDDM [273] with-mal, at least when glycemic control is adequate. It has
been suggested that hypertriglyceridemia results from out adversely affecting glycemic control. A risk of drug-
induced myopathy is present in patients with renal failureincreased hepatic synthesis of VLDL particles [262]. De-
creased high-density lipoprotein cholesterol has been re- [278, 279] and in patients taking cyclosporine, gemfi-
lated to decreased postheparin [263] and adipose tissue brozil, or other lipid-lowering agents. Because diabetic
lipoprotein lipase activity [264]. patients are already predisposed to cataract formation,
Nephropathy in NIDDM appears to alter the lipid HMG-CoA-reductase inhibitors may potentiate this
profile in a more atherogenic direction. Total triglyceride condition.
and VLDL triglyceride concentrations increase mark-
edly [265], whereas total cholesterol is not elevated, at
SUMMARYleast when adjustments are made for gender, age, and
The incidence of ESRD in NIDDM has dramaticallyduration of diabetes [266].
increased, dispelling the mistaken belief that NIDDMLp(a) is highly atherogenic [267, 268], and conse-
had a benign renal prognosis. Although similar clinicalquently its changes in NIDDM are of considerable inter-
and histologic features characterize nephropathy inest. Unfortunately, the available data regarding Lp(a)
IDDM and NIDDM, the two diseases have distinct dif-are confounded by genetic heterogeneity. Small studies
ferences. Proteinuria may be less sensitive for detectinghave failed to find a difference in median Lp(a) concen-
nephropathy in NIDDM. Moreover, nearly one third oftrations in nondiabetic controls and diabetic patients,
patients with NIDDM with albuminuria have nondia-including NIDDM patients with or without nephropathy
betic renal disease. Furthermore, although the absence[265, 269, 270]. Although one study did find higher apo(a)
of retinopathy in IDDM almost excludes diabetic ne-levels in NIDDM patients with microalbuminuria or
phropathy, patients with NIDDM without diabetic reti-macroalbuminuria, this observation was not confirmed
nopathy may still be at risk for diabetic nephropathy.in a more recent case-control study [265].
Finally, the nephropathy of NIDDM occurs at an olderIn nondiabetic patients on dialysis, high cholesterol
age, and the time span between diagnosis and develop-concentrations paradoxically predict better survival [271],
ment of renal disease (5 to 10 years) in NIDDM is shorterpresumably because they are an indication of adequate
than in IDDM (15 to 25 years).nutrition. However, higher total cholesterol and LDL
Lebovitz et al showed that the rate of loss of GFR wascholesterol strongly predict cardiac death in dialyzed
significantly greater in patients with overt proteinuria atdiabetic patients [272]. Treatment with ACE inhibitors
baseline compared with patients with subclinical protein-may lower plasma cholesterol [273], in part by reducing
uria (Fig. 9) [227]. Because of the adverse impact ofproteinuria. In addition, nonpharmacological interven-
microalbuminuria and clinical albuminuria on survivaltions, that is, exercise [274], weight loss, and diet, are
in patients with NIDDM, screening and intervention pro-important. Nevertheless, it may be necessary to use fi-
grams in NIDDM should be implemented early, at thebrates or HMG-CoA reductase inhibitors to lower lipid
levels further. Few studies on pharmacological lipid low- stage of microalbuminuria. Ravid et al extended recom-
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Fig. 9. Effect of baseline UAE on rate of change
of GFR during antihypertensive therapy with en-
alapril in patients with microalbuminuria (A) and
overt albuminuria (B). Data are from Lebovitz
[227]. *P 5 0.0044; **P 5 NS
mendations for early interventions even to normotensive fection, and excessive exercise must be considered when
evaluating microalbuminuria. ACE inhibitors and someNIDDM patients with microalbuminuria [223].
CCBs decrease UAE and may interfere with testing.Cost-benefit analyses for managing IDDM patients
These drugs should be avoided at initial screening. Dur-with microalbuminuria projected considerable benefits
ing therapeutic interventions, however, UAE rates canwith early interventions [280]. Similar analyses for
be determined without withholding these drugs. Persis-NIDDM have not yet been undertaken, but it is expected
tent microalbuminuria needs to be documented by twothat comparable savings would be achieved [66].
or three elevated values over a three to six month period.
A single elevated collection is not adequate [66].
RECOMMENDATIONS
Management of microalbuminuriaScreening for microalbuminuria
The best glycemic control possible should be the goalUrinary albumin excretion (UAE) should be mea-
in microalbuminuric NIDDM patients [66]. If glycemicsured at diagnosis and then annually in all patients with
control is adequate and an increased urinary A/C ratioNIDDM [281]. Standard dipsticks give positive results
persists, an ACE inhibitor is appropriate in normoten-only when the UAE is greater than 250 mg/minute [360
sive and hypertensive patients. Serum creatinine andmg/day]. Products such as Micral Test (Boehringer-Mann-
potassium (K1) levels should be evaluated within oneheim, Mannheim, Germany) and Microbumintest (Ames,
week after initiating ACE inhibitor therapy. If serum
Miles, Elkhart, IN, USA) have been introduced to detect
K1 increases to greater than 5.0 mEq/liter or creatinine
smaller amounts of albumin. Their specificities are fairly increases to greater than 1 mg/dl from baseline, the pa-
low: 82% and 87%, respectively [282]. Microbumintest is a tient should be referred to a nephrologist for further
qualitative test with a positive or negative result; a positive evaluation. In patients with microalbuminuria, a blood
result corresponds to an albumin concentration greater pressure of less than of equal to 130/85 mm Hg should
than 40 mg/liter. Micral is a semiquantitative test with a be targeted [281]. A low-dose diuretic can be added if
range from 0 to 100 mg/liter. A value of 20 mg/liter or this is not achieved with an ACE inhibitor alone [66].
more is considered positive. These are useful screening Additional interventions include treatment for dyslipide-
tests, but microalbuminuria is best diagnosed using quanti- mia and smoking cessation. A comprehensive time course
tative assays [281, 282]. These correlate well with 24-hour for diagnostic and therapeutic interventions in NIDDM
measurements in terms of sensitivity (94%) and specificity patients is summarized in Figure 8.
(96%) [282]. Thus, albumin levels in single-voided urine
Therapy of hypertensionsamples can be used to estimate 24-hour excretion.
Transient causes of microalbuminuria such as hyper- Angiotensin-converting enzyme inhibitors or CCBs are
the first choice for antihypertensive therapy in diabeticglycemia, hypertension, cardiac failure, urinary tract in-
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patients with renal disease. For control of hypertension study, in 1991 the frequency of a body mass index above
25 kg/m2 was 51.4% in the adult German population andin patients with albuminuria (overt diabetic nephropathy),
ACE inhibitors or nondihydropyridine CCBs (diltiazem, 75% in individuals aged between 55 and 64 years [4].
This can be easily confirmed by a casual glimpse at averapamil) are preferred agents [283, 284]. Because re-
ducing albuminuria delays progression in IDDM- and beach with German tourists or at leading German politi-
cians. The same is true for the United States; to quoteNIDDM-related nephropathy, this parameter should be
used as a benchmark for measuring efficacy of therapeu- Klein, “The richest nation in the world is the fattest and
growing fatter. Our behinds, seen on television or ontic interventions [285].
tourists, have become the butt of jokes in every culture
but our own” [295].
PERSPECTIVES
Insights into the pathogenesis of diabetic nephropathy Paradigm shift in NIDDM practices
have provided opportunities for specific therapeutic in- Medical care for patients with NIDDM in general, and
terventions. Thromboxane receptor antagonists have been for proteinuric NIDDM patient in particular, is subopti-
tried in experimental diabetic nephropathy with some suc- mal [296]. ESRD associated with NIDDM (at least in
cess [286]. Kinin-receptor antagonists may block the early the United States) is mainly a disease of poor, older
hemodynamic effects of insulin-like growth factor-1 [287]. African Americans, Hispanics, and Native Americans
Anti-transforming growth factor b antibodies may abro- who have endured substandard medical care during the
gate renal hypertrophy and glomerulosclerosis [288]. interval between the diagnosis of diabetes and the onset
Aminoguanidine, an inhibitor of advanced glycosylation of ESRD [297].
and inducible nitric oxide synthase [289], is currently Most patients with NIDDM are currently being cared
undergoing phase II/III clinical trials in diabetic ne- for by generalists. Many investigators have reported poor
phropathy and may offer a means for reducing the forma- adherence to treatment and screening guidelines for pa-
tion and toxicity of advanced glycation end products. tients with NIDDM [298, 299]. Only 26% of NIDDM
Lovastatin, by inhibiting the mevalonate pathway, matrix patients taking insulin and 5% not taking insulin moni-
synthesis, and transforming growth factor b mRNA ex- tored their blood glucose daily, and education classes
pression, may retard diabetic glomerulosclerosis [291]. were attended by only 35% of patients. Diabetes care
Use of naturally occurring glycosaminoglycans (Sulo- is lacking, further evidenced by data from the Indian
dexidet) in NIDDM may also be of benefit in decreasing Health Service [300]. Uncontrolled hypertension was
UAE [292]. All of these treatment strategies portend present in 33% of patients and metabolic control
possible shifts in the epidemic of NIDDM-related kidney (HbA1C was 7.5% or less or mean blood glucose was
disease. 9.2 mmol/liters or less) in only 29%. There is little evi-
Screening for a genetic predisposition to progressive dence that state-of-the-art treatment is provided to the
renal dysfunction should be considered in the future. majority of diabetic patients with renal disease [301]. A
ACE polymorphisms may play a deleterious role in the survey by Pommer et al documented suboptimal gly-
progression of renal dysfunction in NIDDM [123, 136]. cemic control, blood pressure control, and delayed tim-
Therefore, aggressive ACE inhibition (or perhaps Ang ing of referral to a nephrologist in the majority of diabetic
II receptor blockade) may be warranted for patients who patients with renal disease in Berlin [301]. Initiatives to
are homozygous for the D allele of the ACE polymor- educate primary care providers as to the true renal risk
phism [133]. of NIDDM are crucial.
Although it is a rational strategy to prevent diabetic The DCCT trial showed that achieving and main-
nephropathy in NIDDM patients, it would obviously taining near normal glycemia significantly reduced com-
be more efficacious to prevent NIDDM per se. O’Dea plications, yet it required close monitoring and ongoing
observed normalization of glycemia when diabetic Aus- support from health care teams, ample financial re-
tralian aboriginals were re-exposed to their traditional sources, and patient knowledge and motivation [165].
lifestyle [293]. Eriksson and Lindgarde followed a popu- What has to change to reduce the burden of renal disease
lation of 181 middle-aged men with impaired glucose in NIDDM? To optimize the care of the NIDDM patient,
tolerance [294]. Some of the patients were given a low- we recommend the following: (a) data supporting the
calorie diet and physical exercise, and the others were value of early treatment of microalbuminuria must be
maintained on their habitual lifestyle. After five years, more widely disseminated; (b) education programs fos-
the prevalence of diabetes was markedly less in those tering information about diabetes treatment should con-
who had been switched to a healthier lifestyle (10% vs. tinue to be developed and expanded [302, 303]; (c) suffi-
28.6%). cient resources and funding by governmental agencies
Sadly, Western societies face problems of physical in- should be available to all payors that provide health
care to diabetics; and (d) NIDDM management can beactivity and obesity on a massive scale. According to one
Ismail et al: Renal disease and hypertension in NIDDM 21
man CL, Pettitt DJ, Moffett CD, Teutsch SM, Bennett PH:optimized by using a comprehensive, multidisciplinary
Incidence of end-stage renal disease in type 2 (non-insulin-depen-
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1988educators, and behavioral therapists.
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